

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 April 2025 (10.04.2025)



(10) International Publication Number
WO 2025/074292 A2

(51) International Patent Classification:

A61K 39/12 (2006.01) A61K 9/51 (2006.01)
A61P 31/16 (2006.01)

(21) International Application Number:

PCT/IB2024/059673

(22) International Filing Date:

03 October 2024 (03.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/588,688	06 October 2023 (06.10.2023)	US
63/562,257	06 March 2024 (06.03.2024)	US
63/568,754	22 March 2024 (22.03.2024)	US
63/569,082	22 March 2024 (22.03.2024)	US
63/699,178	26 September 2024 (26.09.2024)	US

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **CHEN, Bo**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **CUI, Liyang**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **HE, Qianjing**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **SHI, Shuai**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **ZHOU, Yajing**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **CHOU, Emily Alexandra**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, NY 10965 (US). **DESOUZA, Ivana Padron**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, NY 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., Legal Division, 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

WO 2025/074292 A2

(54) Title: IMMUNOGENIC COMPOSITIONS

(57) Abstract: The invention relates to lipid nanoparticles, immunogenic compositions and methods for use thereof.